The FDA Is Reviewing BPC-157, TB-500, and Five Other Peptides This July. Here Is What That Actually Means

In April 2026, the FDA announced a formal two-day advisory committee meeting scheduled for July 23 and 24 to evaluate whether seven widely used compounded peptides should be granted official legal status under Section 503A of federal drug law. This review is not a ban, and it is not an approval: it is a structured process with a specific procedural timeline, real stakes for patients and providers, and a public comment window that is open right now. Understanding what is being decided, and how, is the clearest way to cut through the noise surrounding this news.

What Triggered This Review

On April 15, 2026, the FDA announced it would remove a group of compounded peptide substances from Category 2, a designation reserved for bulk drug substances that raise significant safety concerns. The substances removed include BPC-157 (body protection compound 157), TB-500, KPV, GHK-Cu (injectable form), DSIP (delta sleep-inducing peptide), Epitalon, MOTs-C, Semax, LL-37, DiHexa, PEG-MGF, and Melanotan II. Withdrawal from Category 2 signals that the FDA is reconsidering whether the safety concerns that originally placed these compounds on the list were adequately substantiated.

That removal, while welcome news for patients and practitioners in the compounded peptide space, does not by itself confer legal status on these compounds. It simply clears the path for the next step: a formal review by the Pharmacy Compounding Advisory Committee (PCAC) to evaluate whether seven of those substances should be added to the 503A Bulk Drug Substances List, commonly called the 503A Bulks List. That review is what is scheduled for July.

What the 503A Bulks List Is and Why It Matters

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) creates a legal framework under which compounded drugs can be exempt from three major FDA requirements: current Good Manufacturing Practice standards, certain labeling requirements, and the standard new drug approval process. These exemptions are what make patient-specific compounding by licensed pharmacists and physicians legally viable in the United States.

The exemptions are not unconditional. To qualify, a compounded drug product must use a bulk drug substance that meets one of three criteria: it must comply with a United States Pharmacopeia (USP) or National Formulary monograph; it must be a component of an FDA-approved drug; or it must appear on the 503A Bulks List. Most of the peptides being reviewed, including BPC-157, TB-500, MOTs-C, Semax, and Epitalon, do not have USP monographs and are not components of any FDA-approved drug. That puts them squarely in the third category. Their legal use in compounding depends almost entirely on whether they are added to the 503A Bulks List.

For years, many of these compounds have been prescribed through compounding pharmacies while their regulatory status remained unresolved. The July advisory committee meeting is a formal step toward resolving that uncertainty, in one direction or the other.

Which Peptides Are Being Reviewed and for What Uses

The PCAC will evaluate seven substances across the two-day meeting. On July 23, the committee will consider BPC-157 (evaluated for ulcerative colitis), KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTs-C (obesity and osteoporosis). On July 24, the focus shifts to Emideltide, also known as DSIP (opioid withdrawal, chronic insomnia, and narcolepsy), Semax (cerebral ischemia, migraine, and trigeminal neuralgia), and Epitalon (insomnia).

It is worth noting that the uses FDA has identified for review reflect the specific nominations submitted to the agency, not necessarily the full range of ways these compounds are currently used in clinical practice. BPC-157, for example, is far more commonly associated with musculoskeletal repair and gut health than with ulcerative colitis specifically. The nomination process shapes what FDA evaluates, which is one reason the public comment window matters: practitioners with clinical experience across a broader range of uses have the opportunity to put that evidence in the record.

The Timeline and How to Participate

The procedural calendar runs as follows. Through July 9, 2026, the public docket (FDA-2025-N-6895) is open for written comments at regulations.gov. Comments submitted by this date will be formally provided to the PCAC members before the meeting. This is the highest-impact window for patients, practitioners, patient advocates, and compounding pharmacies to submit clinical observations, outcome data, or policy arguments. Comments submitted after July 9 but before the July 22 docket closure will still be considered by FDA, but will not go directly to the committee.

The deadline to register for oral testimony at the meeting is June 30, 2026. Anyone wishing to speak must notify FDA by that date, including a brief description of the evidence or arguments to be presented, names and contact information, a preference for in-person or virtual attendance, and a requested time allotment. If more people register than can be accommodated, FDA may conduct a lottery to select speakers. The meeting itself takes place July 23 and 24 at FDA's White Oak Campus in Silver Spring, Maryland, with a virtual attendance option available.

After the meeting, the PCAC will provide recommendations to FDA. Those recommendations are advisory only: the committee does not make binding decisions. FDA will consider the committee's guidance and, if it concludes a substance is appropriate for listing, will initiate a formal rulemaking process. That process involves its own notice-and-comment period and can take additional months. Listing on the 503A Bulks List is the point at which compounding pharmacies have clear legal footing to produce these compounds.

What This Review Is Not

Two common misreadings of this announcement are worth addressing directly. The first is that removal from Category 2 constitutes an approval or a green light. It does not. It means the FDA is no longer treating these substances as raising significant safety concerns significant enough to block further consideration. The path from Category 2 removal to 503A Bulks List inclusion still requires a formal advisory committee review, a rulemaking process, and a final rule. None of that has happened yet.

The second misreading is that this review represents an imminent ban. It does not. The PCAC review is a structured evaluation process. Its outcome depends on the quality of evidence presented, the committee's assessment of safety and clinical need, and FDA's subsequent rulemaking. Providers who are currently prescribing these compounds through 503A-compliant pharmacies are not in a categorically different legal position today than they were before this announcement. What has changed is that a formal process for resolving the long-standing regulatory uncertainty is now underway, with a public timeline and defined participation opportunities.

What to Watch Between Now and July

FDA will publish background review materials for each substance at least two business days before the July 23 meeting. Those materials will contain the agency's preliminary analysis of the clinical evidence, safety data, and any outstanding concerns for each compound. Reviewing them will provide the clearest available window into how FDA is currently weighing these substances ahead of the committee's deliberations.

The public comment docket is the other document to watch. Comments submitted by providers, medical societies, and patient groups will become part of the public record and can meaningfully inform the committee's recommendations. The docket is publicly accessible at regulations.gov under docket number FDA-2025-N-6895. The quality and volume of clinical input submitted during this window will likely have some bearing on how the committee approaches each compound.

What the July meeting will not resolve is the question of long-term regulatory status for compounds not on this review list. GHK-Cu (topical form), LL-37, and others removed from Category 2 are not on the July agenda. Their path to the 503A Bulks List, if any, runs through a separate nomination and review process. For patients and practitioners whose protocols involve those compounds, the regulatory picture remains the same as it was before April: unresolved, and worth monitoring closely.